Ribociclib with Trastuzumab or Trastuzumab Emtansine in Treating Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer

Status: Active

Description

This phase Ib / II trial studies the best dose of ribociclib with trastuzumab or trastuzumab emtansine and to see how well they work in treating patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes or other places in the body and is human epidermal growth factor receptor 2 (HER2)-positive. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with trastuzumab may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2-positive tumor cells in a targeted way and delivers emtansine to kill them. Giving ribociclib with trastuzumab emtansine or trastuzumab may work better in treating patients with breast cancer.

Eligibility Criteria

Inclusion Criteria

  • Participants must have histologically confirmed invasive breast cancer, with locally advanced or metastatic disease; patients without pathologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation; for subjects in Cohort C, the tumor must also be hormone receptor positive, defined as demonstrating at least 1% tumor cell nuclei staining positive for either ER or progesterone receptor (PR)
  • The primary tumor, and/or metastasis must have been tested for ER, PR and HER 2, and be HER2 positive as defined by the 2013 American Society of Clinical Oncology (ASCO)-College of American Pathologists (CAP) guidelines
  • Measurable disease by RECIST 1.1 (at least one lesion that can be accurately measured in at least one dimension > 20 mm with conventional imaging techniques or > 10 mm with spiral computed tomography [CT] or magnetic resonance imaging [MRI]) or evaluable disease; bone lesions (blastic, lytic, or mixed) in the absence of measurable disease as defined above are also acceptable
  • Cohort A: * Prior treatment with at least one regimen containing trastuzumab and taxane * No prior treatment with T-DM1 that was discontinued due to disease progression or toxicity * No more than 4 prior lines of therapy in the metastatic setting
  • Cohort B: * Must have received prior trastuzumab, pertuzumab, and T-DM1 in neo-adjuvant, adjuvant, or metastatic setting * No limit on prior lines of therapies
  • Cohort C: * Must have received prior trastuzumab, pertuzumab, and T-DM1 in neo-adjuvant, adjuvant, or metastatic setting * Maximum of 5 prior lines of therapy for metastatic breast cancer * Prior treatment with fulvestrant is permitted
  • Menopausal status * Both pre- and post-menopausal patients are permitted into the study; for patients in Cohort C who are pre-menopausal, therapy with a gonadotropin-releasing hormone analogue (leuprolide acetate preferred) must be commenced at least 4 weeks before commencing trial therapy; post-menopausal status is defined either by ** Prior bilateral oophorectomy ** Age greater than 60 ** Age less than 60 years with an intact uterus and amenorrhoeic for at last 12 months ** For patients aged less than 60 years with amenorrhea for less than 12 months (including patients with prior hysterectomy, those who have received hormone replacement therapy, or those rendered amenorrhoeic by chemotherapy), follicle-stimulating hormonal (FSH) levels in the post-menopausal range define the post-menopausal state
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Absolute neutrophil count >= 1.5 x 10^9/L (to be completed within 14 days prior to the date of registration)
  • Platelets >= 100 x 10^9/L (to be completed within 14 days prior to the date of registration)
  • Hemoglobin >= 9 g/dL (to be completed within 14 days prior to the date of registration)
  • Total bilirubin < 1.5 x upper limit of normal (ULN); or total bilirubin =< 3.0 x ULN or direct bilirubin =< 1.5 x ULN in patients with well-documented Gilbert’s syndrome (to be completed within 14 days prior to the date of registration)
  • Serum creatinine =< 1.5 mg/dL or calculated glomerular filtration rate (GFR) >= 50 mL/min (to be completed within 14 days prior to the date of registration)
  • Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x ULN; if liver metastases, ALT/AST =< 5.0 x ULN (to be completed within 14 days prior to the date of registration)
  • International normalized ratio (INR) =< 1.5 (to be completed within 14 days prior to the date of registration)
  • Potassium, total calcium (corrected for serum albumin), magnesium, sodium and phosphorus within normal limits for the institution or corrected to within normal limits with supplements before first dose of study medication (to be completed within 14 days prior to the date of registration)
  • Biopsies: * Cohorts B and C: all patients with disease that is deemed by the treating investigator as safely accessible to biopsy are required to undergo research biopsies as outlined in this protocol * Cohort A: such biopsies are optional
  • A negative pregnancy test =< 7 days prior to treatment for premenopausal women and for women < 1 year after the onset of menopause
  • Ability to understand and the willingness to sign a written informed consent document
  • Participants must be able to swallow ribociclib capsules or tablets
  • Patients must have at screening a standard 12-lead electrocardiogram (ECG) with mean values that meet the following parameters: * Fridericia's correction QT (QtcF) interval at screening < 450 msec (using Fridericia’s correction) * Resting heart rate of 50-90 beats per minute (bpm)

Exclusion Criteria

  • Participants who have had chemotherapy within 14 days prior registration or those who have not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade =< 1 (exception to this criterion: patients with any grade of alopecia are allowed to enter the study); there is no washout period required for trastuzumab or for endocrine therapy; however subjects who received fulvestrant immediately prior to this trial should wait at least 28 days before receiving their first dose of fulvestrant on study
  • Participants who have received radiotherapy =< 2 weeks prior to starting study drug, and who have not recovered to grade 1 or better from related side effects of such therapy (except alopecia and neuropathy) and/or in whom >= 25% of the bone marrow was irradiated
  • Participants who have previously received a cyclin-dependent kinase (CDK) 4/6 inhibitor
  • Participants with central nervous system (CNS) involvement unless they meet ALL of the following criteria: * At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment * Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ribociclib, T-DM1 (Cohort A) and/or trastuzumab (Cohorts B and C) and/or fulvestrant (Cohort C)
  • In general, the use of any concomitant medication deemed necessary for the care of the patient is permitted in this study, except as specifically prohibited below; combination administration of study drugs could result in drug-drug interactions (DDI) that could potentially lead to reduced activity or enhanced toxicity of the concomitant medication and/or ribociclib; patient is currently receiving any of the following medications and cannot discontinue use within 7 days prior to starting study drug: * Known strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5), including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5 * Herbal preparations/medications * Dietary supplements
  • Participants who have any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)
  • Participants who have had major surgery within 2 weeks prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
  • Participants who have clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormalities including any of the following: * History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening * History of documented congestive heart failure (New York Heart Association functional classification III-IV) * Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular (AV) block (e.g. bifascicular block, Mobitz type II) and third-degree AV block * Documented cardiomyopathy * Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening * Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following ** Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia ** Inability to determine the QT interval on screening (QTcF, using Fridericia’s correction) * Systolic blood pressure (SBP) > 160 mmHg or < 90 mmHg at screening
  • Known history of human immunodeficiency virus (HIV)-positivity
  • Active hepatitis B and/or hepatitis C infection
  • Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
  • Concurrent malignancy or a malignancy within 3 years prior to starting study drug, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer; participants with malignancies less than 3 years prior to registration may be considered eligible after discussion with the principal investigator
  • Participants who are currently receiving or have received systemic corticosteroids =< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; the following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
  • Patient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed
  • Participation in a prior investigational study within 21 days prior to enrollment or within 5 half-lives of the investigational product, whichever is shorter
  • Patient with a Child-Pugh score B or C
  • Participants who have a history of non-compliance to medical therapies
  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ribociclib; pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> 5 mIU/mL)
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 8 weeks after study drug discontinuation; highly effective contraception methods include: * Total abstinence when this is in line with the preferred and usual lifestyle of the patient * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment; in case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment * Male sterilization (at least 6 months prior to screening); for female patients on the study, the vasectomized male partner should be the sole partner for that patient * Combination of the two following ** Placement of an intrauterine device (IUD) or intrauterine system (IUS) ** Barrier methods of contraception: condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository
  • Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception; women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago; in the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
  • Sexually active males unless they use a condom during intercourse while taking the drug and for 4 months after stopping treatment and should not father a child in this period; a condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid

Locations & Contacts

Massachusetts

Boston
Brigham and Women's Hospital
Status: Active
Contact: Sara Michell Tolaney
Phone: 617-632-2335
Email: sara_tolaney@dfci.harvard.edu
Dana-Farber Cancer Institute
Status: Active
Contact: Sara Michell Tolaney
Phone: 617-632-2335
Email: sara_tolaney@dfci.harvard.edu
Massachusetts General Hospital Cancer Center
Status: Active
Contact: Aditya Bardia
Phone: 617-724-4000
Email: Bardia.Aditya@mgh.harvard.edu

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of ribociclib in combination with trastuzumab emtansine (T-DM1) among patients with metastatic HER2-positive breast cancer. (Cohort A)

II. To evaluate the clinical benefit rate (CBR - complete response [CR], partial response [PR], and stable disease [SD] at 24 weeks) using the combination of ribociclib with trastuzumab in patients with metastatic HER2-positive breast cancer. (Cohort B)

III. To evaluate the clinical benefit rate (CBR - CR, PR, and SD at 24 weeks) using the combination of ribociclib, trastuzumab, and fulvestrant in patients with metastatic estrogen receptor (ER)-positive, HER2-positive breast cancer. (Cohort C)

SECONDARY OBJECTIVES:

I. To assess the safety and tolerability of ribociclib in combination with T-DM1. (Cohort A)

II. To evaluate the pharmacokinetic (PK) profile of ribociclib in combination with T-DM1. (Cohort A)

III. To explore clinical activity (i.e. objective response rate and progression-free survival) in patients with metastatic HER2-positive breast cancer treated with trastuzumab emtansine (T-DM1) and ribociclib. (Cohort A)

IV. To assess potential biomarkers of response to ribociclib in combination with T-DM1. (Cohort A)

V. To evaluate the objective response rate (as defined by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) in patients with metastatic HER2-positive breast cancer treated with trastuzumab and ribociclib. (Cohort B)

VI. To evaluate progression-free survival (PFS) and overall survival (OS) in patients with metastatic HER2-positive breast cancer treated with trastuzumab and ribociclib. (Cohort B)

VII. To assess the safety and tolerability of ribociclib in combination with trastuzumab. (Cohort B)

VIII. To assess potential biomarkers of response to ribociclib in combination with trastuzumab. (Cohort B)

IX. To evaluate the objective response rate (as defined by RECIST 1.1) in patients with metastatic ER-positive, HER2-positive breast cancer treated with trastuzumab, ribociclib, and fulvestrant. (Cohort C)

X. To evaluate progression-free survival (PFS) and overall survival (OS) in patients with metastatic ER-positive, HER2-positive breast cancer treated with trastuzumab, ribociclib, and fulvestrant. (Cohort C)

XI. To assess the safety and tolerability of ribociclib in combination with trastuzumab and fulvestrant. (Cohort C)

XII. To assess potential biomarkers of response to ribociclib in combination with trastuzumab and fulvestrant. (Cohort C)

OUTLINE: This is a phase I, dose escalation study of ribociclib followed by a phase II study. Patients are assigned to 1 of 3 cohorts.

COHORT A: Patients receive ribociclib orally (PO) once daily (QD) on days 8-21 and trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

COHORT B: Patients receive ribociclib PO QD on days 1-21 or days 1-14 and trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

COHORT C: Patients receive ribociclib PO QD on days 1-21 or 1-28, trastuzumab IV over 30-90 minutes on day 1 and 15, and fulvestrant intramuscularly (IM) on days 1 and 15 of course 1 and day 1 of subsequent courses. Courses repeat every 28 days in the absence if disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days, every 8 weeks for 18 months, and every 12 weeks thereafter.

Trial Phase & Type

Trial Phase

Phase I/II

Trial Type

Treatment

Lead Organization

Lead Organization
Dana-Farber Harvard Cancer Center

Principal Investigator
Sara Michell Tolaney

Trial IDs

Primary ID 15-530
Secondary IDs NCI-2016-00505
Clinicaltrials.gov ID NCT02657343